MediWound (MDWD) Competitors $18.53 -0.11 (-0.59%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$18.53 0.00 (0.00%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MDWD vs. URGN, NUVB, SION, SNDX, QURE, DNA, IMTX, ANAB, CRON, and XERSShould you be buying MediWound stock or one of its competitors? The main competitors of MediWound include Urogen Pharma (URGN), Nuvation Bio (NUVB), Sionna Therapeutics (SION), Syndax Pharmaceuticals (SNDX), uniQure (QURE), Ginkgo Bioworks (DNA), Immatics (IMTX), AnaptysBio (ANAB), Cronos Group (CRON), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry. MediWound vs. Its Competitors Urogen Pharma Nuvation Bio Sionna Therapeutics Syndax Pharmaceuticals uniQure Ginkgo Bioworks Immatics AnaptysBio Cronos Group Xeris Biopharma Urogen Pharma (NASDAQ:URGN) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends. Do institutionals & insiders believe in URGN or MDWD? 91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 5.1% of Urogen Pharma shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is URGN or MDWD more profitable? MediWound has a net margin of -110.45% compared to Urogen Pharma's net margin of -150.68%. MediWound's return on equity of -74.12% beat Urogen Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Urogen Pharma-150.68% -97,487.15% -49.57% MediWound -110.45%-74.12%-30.92% Do analysts rate URGN or MDWD? Urogen Pharma presently has a consensus target price of $32.86, indicating a potential upside of 69.37%. MediWound has a consensus target price of $32.25, indicating a potential upside of 74.04%. Given MediWound's higher probable upside, analysts clearly believe MediWound is more favorable than Urogen Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Urogen Pharma 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00MediWound 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, URGN or MDWD? MediWound has lower revenue, but higher earnings than Urogen Pharma. MediWound is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUrogen Pharma$90.40M9.91-$126.87M-$3.18-6.10MediWound$20.22M9.91-$30.22M-$2.09-8.87 Which has more risk & volatility, URGN or MDWD? Urogen Pharma has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Does the media refer more to URGN or MDWD? In the previous week, Urogen Pharma had 13 more articles in the media than MediWound. MarketBeat recorded 13 mentions for Urogen Pharma and 0 mentions for MediWound. Urogen Pharma's average media sentiment score of 0.38 beat MediWound's score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the media. Company Overall Sentiment Urogen Pharma Neutral MediWound Neutral SummaryUrogen Pharma beats MediWound on 9 of the 16 factors compared between the two stocks. Get MediWound News Delivered to You Automatically Sign up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDWD vs. The Competition Export to ExcelMetricMediWoundMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$201.46M$2.47B$5.47B$9.53BDividend YieldN/A1.81%4.74%4.08%P/E Ratio-8.878.9728.6723.80Price / Sales9.91639.67422.3188.12Price / CashN/A157.7635.4557.96Price / Book6.414.838.275.55Net Income-$30.22M$31.62M$3.24B$259.03M7 Day Performance-8.85%-5.28%-3.63%-4.56%1 Month Performance-3.09%4.38%4.40%4.49%1 Year Performance6.01%-2.49%25.97%18.05% MediWound Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDWDMediWound1.9166 of 5 stars$18.53-0.6%$32.25+74.0%+6.1%$201.46M$20.22M-8.8780URGNUrogen Pharma4.6177 of 5 stars$18.90-0.3%$32.86+73.8%+22.6%$875.52M$90.40M-5.94200News CoverageUpcoming EarningsInsider TradeGap DownNUVBNuvation Bio2.2712 of 5 stars$2.55+2.0%$7.17+181.0%-37.4%$850.66M$7.87M-1.0960News CoverageUpcoming EarningsGap UpSIONSionna TherapeuticsN/A$19.85+3.9%$38.50+94.0%N/A$842.78MN/A0.0035Positive NewsLockup ExpirationSNDXSyndax Pharmaceuticals3.5397 of 5 stars$9.57-0.6%$34.10+256.3%-54.6%$828.64M$23.68M-2.48110Upcoming EarningsQUREuniQure2.5575 of 5 stars$14.98-0.9%$37.82+152.5%+83.0%$827.66M$27.12M-3.41500Trending NewsEarnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionDNAGinkgo Bioworks1.1505 of 5 stars$13.94-0.1%$8.50-39.0%N/A$817.10M$227.04M-1.52640News CoverageGap DownIMTXImmatics2.1547 of 5 stars$6.67+1.7%$14.67+119.9%-45.1%$797.37M$144.15M-39.23260ANABAnaptysBio2.2051 of 5 stars$26.59-1.3%$47.13+77.2%-27.6%$791.51M$91.28M-5.48100News CoverageUpcoming EarningsCRONCronos Group2.3154 of 5 stars$2.06+0.5%N/A-17.0%$790.65M$117.61M15.85450Upcoming EarningsXERSXeris Biopharma3.3716 of 5 stars$5.07+1.0%$6.25+23.3%+121.4%$785.05M$203.07M-16.90290News CoveragePositive NewsUpcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies Urogen Pharma Alternatives Nuvation Bio Alternatives Sionna Therapeutics Alternatives Syndax Pharmaceuticals Alternatives uniQure Alternatives Ginkgo Bioworks Alternatives Immatics Alternatives AnaptysBio Alternatives Cronos Group Alternatives Xeris Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDWD) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediWound Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediWound With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MDWD Stock Alerts